Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation

Bone Marrow Transplantation

Volumn 26, Issue 3, 2000, Pages 243-250

  Wasch R ^a,b   Reisser, S ^a   Hahn, J ^c   Bertz, H ^a   Engelhardt, M ^a   Kunzmann, R ^a   Veelken, H ^a   Holler, E ^c   Finke, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Allogeneic transplantation; Mixed chimerism; Reduced conditioning; Regimen related toxicity

Indexed keywords

AMSACRINE; CARMUSTINE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LYMPHOMA; MELANOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; THROMBOSIS;

EID: 0041892247     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702512     Document Type: Article

References (35)

1. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med 1981; 304: 1529-1532.
2. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. New Engl J Med 1989; 320: 828-834.
3. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 1995; 86: 2041-2050.
4. Bertz H, Burger JA, Kunzmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997; 11: 281-283.
5. van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977-982.
6. Clift RA, Buckner D, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
7. Clift RA, Buckner D, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77: 1660-1665.
8. Holler E, Ertl B, Hintermeier-Knabe R et al. Inflammatory reactions induced by pretransplant conditioning - an alternative target for modulation of acute GVHD and complications following allogeneic BMT? Leuk Lymphoma 1997; 25: 217-224.
9. Storb R, Cong Y, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
10. Storb R, Cong Y, Barnett T et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999; 94: 1131-1136.
11. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
12. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
13. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
14. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaematopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
15. Childs R, Bahceci E, Clave E et al. Non-myeloablative allogeneic peripheral blood stem cell transplants (PBSCT) for malignant diseases reduces transplant-related mortality (TRM). Blood 1998; 92 (Suppl. 1): 137a (Abstr. 552).
16. Childs RW, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044-2049.
17. Engelhardt M, Bertz H, Afting M et al. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral blood progenitor cells from allogeneic donors and CD34+ immunoselection. J Clin Oncol 1999; 17: 2160-2172.
18. Bertz H, Potthoff K, Mertelsmann R, Finke J. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19: 1169-1173.
19. Budowle B, Chakraborty R, Giusti AM et al. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet 1991; 48: 137-144.
20. Edwards A, Hammond HA, Jin L et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12: 241-253.
21. Horn GT, Richards B, Klinger KW. Amplification of a highly polymorphic VNTR segment by the polymerase chain reaction. Nucleic Acids Res 1989; 17: 2140.
22. Boerwinkle E, Xiong W, Fourest E, Chan L. Rapid typing of tandemly repeated hypervariable loci by the polymerase chain reaction: application to the apolipoprotein B 3′ hypervariable region. Proc Natl Acad Sci USA 1989; 86: 212-216.
23. Bader P, Hölle W, Klingenbiel T et al. Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res 1996; 16: 1759-1764.
24. Förster HH, Wäsch R, Kretschmar T et al. Genetic markers on chromosome 19p and prenatal diagnosis of HLA-class-II-deficient combined immunodeficiency. Pediatr Res 1995; 38: 812-816.
25. Wäsch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed chimerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic transplantation. Br J Haematol 2000; 109: 743-750.
26. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
27. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
28. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
29. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
30. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
31. Bertheas M, Lafage M, Levy P et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood 1991; 78: 3103-3106.
32. Hill RS, Petersen FB, Storb R et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811-816.
33. Przepiorka D, Smith TL, Folloder J et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
34. Cong Y, Seidel K, Nash RA et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-non-identical unrelated marrow grafts. Blood 1998; 91: 2581-2587.
35. Baurmann H, Nagel S, Binder T et al. Kinetics of graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood 1998; 92: 3582-3590.